LOY-003, a daily tablet for large and giant breeds, has earned RXE acceptance, the third such milestone for a Loyal lifespan drug.
Great Danes have an average life expectancy of six to eight years, while a Chihuahua can live up to 20. Loyal, the animal health company trying to bring the first FDA-approved lifespan drugs for dogs to market, thinks that gap is a clue about aging itself. On 16 September, it announced another regulatory step built on that idea.
The FDA has accepted Reasonable Expectation of Effectiveness (RXE) for LOY-003, Loyal’s drug program for large and giant-breed dogs. It is the third time the company has gotten there, after LOY-001, also for large dogs, and LOY-002 for senior dogs. According to Loyal, LOY-001 was the first drug to achieve RXE acceptance for lifespan extension in any species [1].
In plain terms, RXE means the FDA agrees a drug can reasonably be expected to work. Loyal put it this way in its announcement: “The FDA now agrees that LOY-003 can reasonably be expected to be effective at achieving this.” That is short of approval. The company’s stated mission is to develop the first FDA-approved drugs indicated to preserve quality of life, delay frailty and extend lifespan, and RXE is one step along that road. Loyal itself talks about advancing its portfolio “towards hopeful approval,” and no product is on the market yet.
The size problem
Loyal describes the link between size and lifespan as a phenomenon unique to dogs, and likely a consequence of historic inbreeding. Small breeds outlive big ones by a wide margin, which is the reverse of what you would guess.
The company points to two hormones, growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Both help set how big a dog gets, and both are tied to how long it lives. Loyal says big dogs can carry anywhere from about 2 to 30 times as much IGF-1 as small and medium dogs, with higher levels going hand in hand with bigger adult size and shorter lives. Its summary is that “the same biological pathway that causes big dogs to grow large and fast ultimately accelerates their aging and makes them die sooner.”
LOY-003 is a once-daily oral tablet that lowers GH and IGF-1 levels, with the aim of preserving quality of life and extending lifespan in large and giant breeds. The company calls the problem it is targeting “big dog, short life.”
A dial older than dogs
This pathway is one of the oldest known dials in biology. Loyal’s post points to Dr Cynthia Kenyon’s 1993 paper, in which mutating a gene that regulates insulin/IGF-1 signaling in roundworms doubled their lifespan. Decades of work since then, the company says, have shown that turning down GH and IGF-1 signaling reproducibly lengthens life and delays certain chronic diseases across species. It calls these among the most conserved regulators of lifespan ever discovered.
That is why a dog drug is interesting to anyone following human aging research. The bigger story may be what a regulator has just agreed to look at. Regulators have historically been wary of treating aging as something a drug can be approved for. Here, the FDA has now accepted three times that a drug with lifespan as its primary indication can reasonably be expected to work, at least at this stage of the process.
Some caution is due. The post was written by one of Loyal’s own scientists, and it includes no data on how much longer dogs might live. It says nothing about side effects and gives no timeline for a launch. RXE says a drug can reasonably be expected to work, which is a different thing from showing that it did. Loyal is also focused on dogs, and nothing in the announcement points to a human version of a GH-lowering drug.
Loyal does make a point of separating itself from the crowd. The post says that, unlike traditional animal health companies and other longevity biotechs, it is developing drugs that explicitly aim to extend the healthy lifespans of dogs. Two of its three RXE acceptances are for large dogs and one is for seniors, so the company is already sketching out different corners of the canine population.
Preventive medicine for pets
Loyal says it hopes to create a new category of therapeutics, preventive medicines developed explicitly to help dogs live longer, healthier lives. It describes its own work as forging the regulatory and clinical path to take lifespan science out of the laboratory.
If that category takes shape, the reaction from vets, owners and regulators will be a useful signal for anyone thinking about aging drugs in people. Dogs live alongside us, get many of the same age-related problems, and have owners who notice a lot about how their pets are doing. That makes them a useful preview of how the public might respond to a medicine that aims to stretch healthy years.
In the meantime, Loyal says its science team will keep digging into the biology of canine aging, looking for new pathways that could lead to more therapies.
